News November 16, 2026

CBL-514: The Fat-Cell-Killing Injection, Checked Against the Actual Trials

CBL-514 went viral as a shot that makes belly fat cells self-destruct. We read the registered trials, the peer-reviewed papers, and the EASD visceral-fat data to separate what is shown from what is hype.


On November 15 and 16, 2026, CBL-514 suddenly took over a corner of X.

The pitch going around was simple:

  • an injection that makes fat cells self-destruct instead of just shrinking
  • fat loss right where the needle goes in
  • 69.6% of people losing at least 150 mL of belly fat in Phase 2, versus none on placebo
  • and 320 people now in a Phase 3 trial1

Every one of those points traces back to something real.

But several of them lose important context on the way to a tweet. So we went back to the sources: the four peer-reviewed CBL-514 papers, the ClinicalTrials.gov records for all 16 registered CBL-514 studies, Caliway’s own press releases, and the independent expert reaction to the visceral-fat data.

Here is what the evidence actually supports.

The short version

  • CBL-514 is real, and the data are better than most “fat-dissolving” hype. There are randomized, placebo-controlled trials, and the two abdominal ones are now peer-reviewed.
  • It is a local fat-reduction drug, not a weight-loss drug. Trial participants had to keep their weight stable, and in the published Phase 2 study, body weight barely moved.
  • The effect size is moderate. The trials reported roughly 150–210 mL less fat in a treated 300 cm² patch of abdomen. That is a visible change, but not liposuction volume.
  • The famous 69.6% comes from 23 people. About half the trial’s participants did not complete it.
  • Almost everyone gets injection-site reactions. In the published Phase 2 study, 18.4% of treated participants had severe injection-site pain.
  • The visceral-fat headlines rest on a small conference subgroup that has not been peer-reviewed.
  • It is not approved anywhere. The first pivotal Phase 3 trial started in September 2026, and its primary completion is estimated for July 2027.
  • It is not a peptide, and its chemical structure has not been published. That matters if a research vial labeled “CBL-514” shows up in your feed.

What CBL-514 is

CBL-514 is developed by Caliway Biopharmaceuticals, a company in New Taipei City, Taiwan, that was founded in 2012 and listed on the Taiwan Stock Exchange (6919) in October 2024.2

Caliway describes it as a first-in-class small-molecule injectable being developed under the FDA’s 505(b)(1) pathway, which is the route for a new chemical entity rather than a reformulation of an existing drug.23

A few things about its identity are worth being clear on:

  • It is not a peptide. Caliway’s releases and the peer-reviewed trial papers call it a small molecule.45
  • No structure has been published. We could not find a chemical structure, CAS number, or molecular formula in the papers, the trial registry, or Caliway’s releases.
  • It may not be a single compound. When Caliway announced completion of its CBL-0205 trial, it described CBL-514 as “a combination of multiple APIs, including CBL-A1 and CBL-A2.” That trial compared CBL-514 against those two components on their own.6

That last point explains one of CBL-0205’s more interesting results. The full CBL-514 product removed more than twice as much fat as either named component on its own (166.6 mL versus 69.9 mL and 70.5 mL), according to Caliway’s results release.3

The proposed mechanism

According to the Phase 2a paper, Caliway’s preclinical work found that CBL-514:

  • inhibits DYRK1B, a kinase that helps cells survive
  • increases caspase-3 activation and the Bax/Bcl-2 ratio, two standard markers of apoptosis
  • induces dose-dependent apoptosis in cultured fat cells (3T3-L1 adipocytes) and in animals7

One caveat sits in the citation itself. The paper attributes these findings to “unpublished confidential reports” from Caliway.7

The human trials did not measure apoptosis or count fat cells. They measured fat thickness and volume with ultrasound and MRI. So “it kills fat cells” is the company’s mechanism, backed by its own preclinical data. What the clinical trials show is that fat volume goes down in the treated area.

Why “kill, don’t shrink” got people excited

The biology behind the viral framing is solid.

The landmark 2008 Nature study by Spalding and colleagues dated fat cells using carbon-14 left over from nuclear bomb tests. It found that:

  • the number of fat cells stays roughly constant in adulthood, in both lean and obese people
  • it does not fall even after marked weight loss
  • about 10% of fat cells are replaced each year, so the total holds steady through constant turnover8

Diet, exercise, and GLP-1 drugs mostly shrink existing fat cells. The cells stay in place and can refill.

But CBL-514 would not be the first treatment to permanently remove fat cells:

  • Liposuction physically removes them.
  • Cryolipolysis (fat freezing) kills them with cold.
  • Deoxycholic acid (ATX-101, sold as Kybella) destroys them chemically. It is the only FDA-approved injectable for fat reduction, and only for fat under the chin. Its known side effects include skin necrosis, ulceration, and injury to a facial nerve.4

What makes CBL-514 different is the combination Caliway is aiming for: an injectable that works on large areas like the abdomen, kills fat cells through apoptosis rather than by dissolving them, and avoids the necrosis and nerve injury seen with deoxycholic acid.

That is a meaningful niche. It is just narrower than “a new fat-loss drug.”

Key registered CBL-514 trials

ClinicalTrials.gov lists 16 CBL-514 studies.9 Here are the ones that matter most for the abdominal-fat program. The rest include cellulite, pharmacokinetic, and earlier Dercum’s studies, plus a second 250-person re-treatment study that is not yet recruiting.

Trial Phase People Design What it found
NCT04699669 1 40 Double-blind dose escalation, Australia, 2018–19 Safety and pharmacokinetics, doses up to 320 mg10
NCT04698642 2a 43 Open-label, no placebo, three doses At 2.0 mg/cm², fat volume fell 24.96% (−119.8 mL) in the per-protocol group7
NCT04897412 2 76 Single-blind, placebo, 2:1 The source of the “69.6%” figure. Peer-reviewed in 20254
NCT05736107 (CBL-0204) 2b 108 Single-blind, placebo, 1:1 76.7% (23 of 30 assessed) improved at least 1 grade on the clinician fat scale, versus 18.9% (7 of 37) on placebo. MRI showed −152.9 mL (−20.3%). Peer-reviewed in 20265
NCT06005441 (CBL-0205) 2b 173 Double-masked, placebo plus two single-component arms 54.2% lost at least 20% of fat volume by MRI, versus 0% on placebo. Average change was −166.6 mL versus +15.7 mL. Company-reported only3
NCT07140939 (SUPREME-01) 3 320 (target) Triple-blind, placebo, US and Canada Recruiting since September 1, 2026. Primary completion estimated July 202711
NCT07526974 (SUPREME-02) 3 320 (target) Triple-blind, placebo, US, Canada, and Australia Not yet recruiting. Primary completion estimated August 202712
NCT07733947 3b 300 (target) Follow-up of the Phase 3 participants, no new drug given Durability and safety at 6, 9, and 12 months13
NCT07608770 2b 250 (target) Placebo-controlled, with re-treatment, Australia Recruiting14

There is also a separate program in Dercum’s disease, a rare condition that causes painful fatty lumps (lipomas):

  • In a 12-person open-label Phase 2a study, the median lipoma volume fell 46–59% and pain scores dropped about 4 points on a 0–10 scale.15
  • A 19-person placebo-controlled Phase 2 trial (NCT06303570) reported a 3.1-point pain reduction with the drug versus 1.9 with placebo at week 20. That result is company-reported.1617

The FDA granted CBL-514 Orphan Drug and Fast Track designations for Dercum’s disease in March 2024.18

The 69.6% number, unpacked

This is the statistic everyone is quoting. It comes from the 2025 Aesthetic Surgery Journal paper by Gold and colleagues.4

How the trial worked

  • 76 adults were randomized 2:1: 50 to CBL-514 and 26 to saline placebo.
  • Each treatment was 25 to 50 injections of 2.4 mL into the abdomen, placed 2.45 cm apart. The dose was 2 mg/cm², up to 600 mg per session.
  • Participants got up to 4 sessions, four weeks apart, with check-ups 4 and 8 weeks after the last one.
  • Anyone whose weight moved 3 kg or more from baseline was removed from the study.
  • 94% of the CBL-514 group was female.

What the 69.6% actually means

At the 8-week follow-up, 16 of 23 CBL-514 participants still being assessed had lost at least 150 mL. In the placebo group, 0 of 16 had.4

That gives the 69.6%. A few details change how it reads:

  • About half of participants did not finish. The non-completion rate was 49.3%. Reasons included loss to follow-up, withdrawal, weight changes, missed visits, and adverse events. Only 30 of the 76 made it into the per-protocol analysis.
  • It was single-blind. Participants were blinded by visual barriers. Investigators, site staff, and the sponsor were not blinded.
  • “150 mL” is calculated, not measured directly. Fat thickness was measured by ultrasound at four points. Volume was then computed as average thickness × a fixed 300 cm² treatment area. That means the 150 mL threshold equals about 5 mm of average thickness loss across those four points.
  • The sponsor ran the analysis. Caliway funded the study and was involved in its design, data analysis, and writing. Three of the nine authors are Caliway employees and shareholders.

The more useful numbers

The average effect is more informative than the responder rate. In the intention-to-treat population, treated participants lost an estimated 209 mL of fat from baseline at 8 weeks. The difference versus placebo was 216 mL.

In the per-protocol group, the figures were higher, at about 279 mL lost and a 277 mL difference versus placebo. The single best responder lost more than 750 mL.4

For scale, 200 mL is a little under a cup.

The paper’s conclusion calls this “comparable to that achieved with liposuction.” That comparison should be read cautiously, because liposuction is not restricted to a 300 cm² patch.

The later CBL-0204 trial used MRI instead of the ultrasound calculation. It found about 153 mL lost on average (−20.3%).5 That fits the same range.

Body weight did not change, by design

In the published Phase 2 study, the CBL-514 group’s average weight changed by +0.02 kg at 8 weeks. The placebo group’s changed by −0.26 kg.4

So when people describe CBL-514 as a “fat loss drug,” it is worth being precise. It reduces fat where it is injected. It has not been shown to reduce total body weight in humans.

Side effects: mild, but nearly universal

The published Phase 2 safety table is more informative than the “favorable safety profile” summary line.4

Treatment-related reaction CBL-514 (n = 49) Placebo (n = 26)
Injection-site erythema (redness) 93.9% 69.2%
Injection-site pain 93.9% 65.4%
Itching 85.7% 42.3%
Swelling 83.7% 65.4%
Warmth 83.7% 30.8%
Discoloration 71.4% 11.5%
Induration (hardening) 61.2% 7.7%
Severe reaction (all were injection-site pain) 18.4% 0%

Other details from the same study:

  • Of the 63 participants with injection-site pain (both groups combined), 60.3% needed medication, mostly over-the-counter painkillers.
  • For 90.5% of them, the pain resolved within a week.
  • Two treated participants stopped because of side effects (pain and discoloration).
  • One participant with pre-existing high cholesterol had hyperlipidemia that investigators judged probably related to treatment.
  • The study saw no skin necrosis, ulceration, or nerve injury, which are the known problems with deoxycholic acid.

The bigger gap is time. Follow-up in the published studies ran 8 to 12 weeks after the last treatment. Nobody has published what the treated area looks like after a year.

That is exactly what the Phase 3b extension study (NCT07733947) is designed to measure, at 6, 9, and 12 months.13

The visceral-fat headlines

The second wave of coverage started in early October 2026, when outlets from Science News to Fox News ran headlines about the drug cutting the “dangerous” fat around organs by about 12%. These followed a Caliway presentation at the EASD 2026 meeting in Milan.192021

What was presented

The presentation was an MRI subgroup analysis pooled from two Phase 2b trials, CBL-0204 and CBL-0205.

  • Visceral fat (the fat around the organs) was measured at the L2–L3 level of the spine.
  • The analyzed participants had a BMI of 22–30.
  • At 4 weeks after the final treatment, visceral fat fell by about 11–12% in the CBL-514 group and rose by about 5–6% on placebo.
  • At the later follow-up (8 or 12 weeks), the CBL-514 group was still about 7–10% below baseline, while the placebo group was about 12–18% above it.2021

Five reasons to hold that loosely

1. The reported numbers do not agree with each other.

  • HCPLive reported 46 participants (26 on CBL-514, 20 on placebo), a baseline of 642.5 mL, and a 4-week change of −10.9%.
  • The EASD press release, as republished by ScienceDaily, reported 41 participants (23 and 18), a baseline of 563.85 mL, and a change of −12.01%.

These look like two different cuts of the same data. Neither has gone through peer review.2021

2. The placebo group drove much of the gap.

Prof. Justin Rochford of the University of Aberdeen pointed out that the placebo group gained weight and fat, which makes the apparent effect of CBL-514 look larger.22 An 11.76% rise in the placebo group over a few months is unusually large for people who were asked to keep their weight stable.

3. The population was not obese.

Some headlines said “in obesity,” but the analyzed participants had a BMI of 22–30, which covers normal weight and overweight. Both parent trials excluded anyone with a BMI of 30 or higher, and so do the Phase 3 trials.1112

4. It is unclear how the drug reached visceral fat.

CBL-514 is injected into fat under the skin, not into the abdominal cavity where visceral fat sits. None of the coverage explained how it would get there. A systemic effect, a shift in where fat gets stored, and measurement artifacts all remain possible explanations.

5. Losing fat under the skin is not automatically healthy.

Rochford also noted that subcutaneous fat can be a healthy place to store energy. In lipodystrophy, where that storage is missing, fat shifts to other organs, especially the liver. He raised this as something to check for, not as a known effect of CBL-514. He called for liver fat, blood lipids, and blood sugar control to be measured.22

Dr. Marie Spreckley of the University of Cambridge made the broader point: the human data so far “do not establish whether the treatment helps people lose weight,” let alone whether it improves health.22

The GLP-1 angle: interesting, and still in animals

Caliway is now positioning CBL-514 as a partner to GLP-1 drugs. The idea is that GLP-1s shrink fat cells, and when people stop taking them, those cells refill. Fewer fat cells might mean less room for the weight to come back.

The evidence so far:

  • Animal data (ADA 2026): After tirzepatide was stopped, animals given tirzepatide alone showed 46.1% weight regain, versus 17.1% for animals that also got CBL-514. The release did not give the model or doses, and it is not a peer-reviewed publication. Rochford’s comment describes the combination work as rat data.2322
  • A human combination trial is cleared but not running yet. In August 2026, the FDA cleared an IND for CBL-0201WR, a randomized, single-blind, placebo-controlled Phase 2 study of CBL-514 with tirzepatide in about 120 adults. The primary endpoint is MRI-measured abdominal fat under the skin. Body weight and visceral fat are only exploratory endpoints.2 We could not find a ClinicalTrials.gov record for it as of November 16, 2026.

There is also a precedent worth knowing. The first randomized trial of whether removed fat comes back was Hernandez et al., 2011. It randomized 32 non-obese women to small-volume liposuction or no surgery.

The overall body-fat advantage from liposuction was gone by one year. Fat stayed reduced in the treated thighs, but it came back in the abdomen.24

Removing fat cells in one place does not remove the energy surplus that fills them. Whether CBL-514 behaves differently is exactly what the extension and combination trials need to show.

Fact-checking the viral claims

Claim What the record shows
“Kills fat cells right where it goes in” Plausible, mostly company-sourced. Fat volume falls in the injected area across several randomized trials. The apoptosis mechanism comes from Caliway’s unpublished preclinical reports, and no human trial counted fat cells.
“Your fat cell number stays the same for life” True for adults. The total number holds steady, with about 10% of fat cells replaced each year.8
“69.6% lost ≥150 mL, versus none on placebo” Accurate quote, thin base. It was 16 of 23 versus 0 of 16 at week 8, in a 76-person single-blind trial where 49.3% did not finish.
“320 people in Phase 3” Partly. 320 is SUPREME-01’s enrollment target, and recruiting began September 1, 2026. A second 320-person Phase 3 is registered but not yet recruiting, and a 300-person extension study follows them.
“It can SPOT REDUCE fat” That is the intended use. It reduces fat locally in the treated area. It is not a total-body fat-loss or weight-loss drug.
“Cuts organ fat by 12%” Small, not peer-reviewed subgroup with inconsistent reported numbers and a placebo group that gained fat.
“Fat doesn’t rebound” Not shown in humans. The only regain data come from animals.

Can you get CBL-514 now?

Not legitimately.

CBL-514 is not approved anywhere, and the only legitimate way to receive it is as a participant in a registered trial. The EASD coverage described it as an experimental drug still in development.21

The research-chemical market has noticed it anyway. At least one vendor in the catalogs PeptideBenchmark tracks has listed a “CBL-514 Research Compound 20MG Vial.” It was sold out when we checked on November 16, 2026.

That listing has some problems that are specific to this compound:

  1. There is no public reference standard. CBL-514’s structure has not been published, and Caliway describes it as a combination of multiple active ingredients. Without a known structure or reference material, a lab cannot confirm that a vial contains CBL-514. A COA showing high purity of something does not establish identity here.
  2. The trial dose comes from a mapped injection grid, not a vial. In the later Phase 2 trials, a single session was up to 600 mg, delivered as up to 50 evenly spaced injections across the abdomen. A 20 mg vial is about 1/30th of one session. We point this out to show the mismatch, not as dosing guidance.
  3. The safety data belong to the trial formulation. Caliway’s injection-site profile, including severe pain in nearly 1 in 5 participants, comes from a specific manufactured formulation at a specific concentration and spacing. None of that carries over to an unidentified powder.
  4. It is not a peptide. Like SLU-PP-332, it is sold to peptide buyers without being one. Peptide-focused testing does not automatically apply to it.

When could it actually be available?

Based on the registry dates:

  • SUPREME-01: primary completion estimated July 2027, study completion September 202711
  • SUPREME-02: primary completion estimated August 2027, study completion October 202712
  • Extension study: primary completion estimated August 202813

Both Phase 3 trials use a demanding primary endpoint: at least a 2-grade improvement on a 5-point abdominal fat rating scale. For SUPREME-01, that improvement has to show up on both the patient-rated and clinician-rated versions of the scale.

In CBL-0204, only 32% of treated participants reached a 2-grade improvement on the clinician scale, according to Caliway’s release.25 Clearing that bar against placebo is achievable, but it is not guaranteed.

If both Phase 3 trials succeed and the timelines hold, a US filing would most plausibly come in 2028, with any approval after that. That is our estimate, not a company projection.

The bottom line

CBL-514 is one of the more credible “fat-dissolving injection” candidates to come along. It has multiple randomized trials, four peer-reviewed papers, consistent abdominal fat reductions of about 150–210 mL, and none of the tissue-necrosis problems associated with deoxycholic acid.

It is also less than what the viral posts imply:

  • It is a body-contouring drug for people who are already near a healthy weight, not an obesity treatment.
  • Most of the headline numbers come from small, sponsor-run trials with heavy dropout.
  • The visceral-fat and GLP-1 regain stories are still a conference subgroup and rat data.
  • Injection-site pain and hardening are common, and long-term durability is unknown.
  • Any gray-market vial of “CBL-514” cannot be identity-verified against a public reference.

The two numbers worth watching are SUPREME-01’s primary result, expected after mid-2027, and the 12-month follow-up from the extension study. Those will show whether destroyed fat cells stay gone, and whether the fat comes back somewhere else.

Sources

Footnotes

  1. Viral post on X, November 16, 2026 ↩

  2. Caliway press release, August 25, 2026 ↩ ↩2 ↩3

  3. Caliway CBL-0205 results release ↩ ↩2 ↩3

  4. Gold et al., Aesthet Surg J (2025), NCT04897412 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  5. Lorenc et al., Aesthet Surg J (2026), NCT05736107 ↩ ↩2 ↩3

  6. Caliway CBL-0205 completion release ↩

  7. Goodman et al., Aesthet Surg J (2022), NCT04698642 ↩ ↩2 ↩3

  8. Spalding et al., Nature (2008) ↩ ↩2

  9. ClinicalTrials.gov: NCT04699669 ↩

  10. ClinicalTrials.gov: NCT07140939 (SUPREME-01) ↩ ↩2 ↩3

  11. ClinicalTrials.gov: NCT07526974 (SUPREME-02) ↩ ↩2 ↩3

  12. ClinicalTrials.gov: NCT07733947 ↩ ↩2 ↩3

  13. ClinicalTrials.gov: NCT07608770 ↩

  14. Herbst et al., JAAD Int (2026) ↩

  15. ClinicalTrials.gov: NCT06303570 ↩

  16. Coverage of Caliway’s CBL-0202DD Dercum’s disease results (September 2026) ↩

  17. Pharmacy Times: FDA grants Orphan Drug designation for CBL-514 in Dercum disease (March 2024) ↩

  18. Science News, October 8, 2026 ↩

  19. HCPLive, October 7, 2026 ↩ ↩2 ↩3

  20. ScienceDaily: EASD release on CBL-514 ↩ ↩2 ↩3 ↩4

  21. Science Media Centre expert reaction, October 1, 2026 ↩ ↩2 ↩3 ↩4

  22. Caliway ADA 2026 release ↩

  23. Hernandez et al., Obesity (2011) ↩

  24. Caliway CBL-0204 results release ↩

Common questions

What is CBL-514?

CBL-514 is an investigational injectable drug from Caliway Biopharmaceuticals (Taiwan) for reducing subcutaneous fat in a treated area. Caliway calls it a first-in-class small-molecule drug that makes fat cells undergo apoptosis (programmed cell death). It is not a peptide, and its chemical structure has not been publicly disclosed.

Is CBL-514 FDA approved?

No. As of November 16, 2026, CBL-514 is not approved anywhere. The first pivotal Phase 3 trial, SUPREME-01 (NCT07140939), began recruiting toward a target of 320 adults in September 2026, with primary completion estimated for July 2027. A second 320-person Phase 3, SUPREME-02 (NCT07526974), was listed as not yet recruiting.

Is CBL-514 a weight-loss drug?

Not in the trials run so far. Every completed abdominal efficacy trial required participants to keep their body weight stable, and the published Phase 2 study reported essentially no change in body weight. CBL-514 is being developed to reduce fat in the injected area, not to lower total body weight. Its use alongside GLP-1 drugs is still at the animal-data stage, with a human combination trial cleared by the FDA but not yet reported.

Does CBL-514 reduce visceral fat?

A small, not-yet-peer-reviewed subgroup analysis presented at EASD 2026 reported that visceral fat measured by MRI fell about 11–12% at 4 weeks after treatment in people given CBL-514, while it rose in the placebo group. The subgroup was about 40 to 46 people with a BMI of 22–30, and an outside expert noted that the placebo group gaining fat makes the difference look larger.

Can you buy CBL-514 from peptide vendors?

At least one vendor in the catalogs PeptideBenchmark tracks has listed a 20 mg 'CBL-514' research vial. Because CBL-514's structure is not public, there is no public reference standard a lab could use to confirm a vial's identity. In the later Phase 2 trials it was given as a defined formulation at up to 600 mg per session, spread across 25 to 50 injections. It is also not a peptide.